PreveCeutical Medical Inc. PRVCF Archives - Page 4 of 6

ThursdayJun 21, 2018 3:04 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Takes Aim at Massive Alternative Medicines Market

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pursuing therapies for a variety of physical ailments through nature-centric research. An article discussing the company reads: “PreveCeutical’s drive to develop its Nature Identical line of biopharmaceuticals positions it to take advantage of the mainstreaming of the complementary and alternative medicine market, a sector that’s expected to generate $196.87 billion in revenues by 2025, according to a report by Grand View Research, Inc. (http://ibn.fm/LN4EP). The market has been driven by the popularity of herbal dietary supplements and other wellness therapies like yoga and acupuncture, but the recent global clamor for…

FridayJun 15, 2018 3:09 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Positioned in Growing Markets with Novel Therapies and Groundbreaking Delivery Platform

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is positioned in rapidly-growing markets with innovative preventative therapies and a groundbreaking cannabidiol (“CBD”) drug delivery platform. An article discussing this reads, “Research has shown CBD to be non-psychoactive and to have anti-inflammatory, anti-anxiety and anti-emetic properties (http://ibn.fm/KnsIZ). Following nasal administration, the formulations gel rapidly with mucosal tissue to facilitate direct nose-to-brain delivery of cannabinoids. The gel substantially improves bioavailability and provides controlled cannabinoid release, staying in the nasal passages for up to seven days.” To view the full article, visit http://ibn.fm/XczQC About PreveCeutical Medical Inc. PreveCeutical is a health sciences…

WednesdayJun 13, 2018 11:25 am

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Extends Share Warrants Expiry amid Growing Alternative Medicine Popularity

PreveCeutical moves on recent stock split to boost share appeal Company’s organic therapeutics aim to relieve maladies for patients with diabetes, brain injuries and other conditions Alternative medicines market expected to generate nearly $200 billion in revenues by 2025 PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) continues working to shore up its share appeal while seeking remedies for a variety of physical ailments through its nature-centric research to help patients with type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain. PreveCeutical Medical completed a forward stock split last month on the basis of five…

MondayJun 11, 2018 1:04 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Set to Capitalize on Growth of Dietary Supplement, Drug Delivery Markets

Two separate market research reports predict 7.0 percent and 2.9 percent CAGR, respectively, in PreveCeutical’s areas of operation PreveCeutical developing Sol-Gel, an innovative medicine delivery platform Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is uniquely positioned to capitalize of the growth of two different markets in which it currently operates: dietary supplements and drug delivery systems. Two separate market research reports indicated recently that these sectors are expected to grow a projected 7.0 percent and 2.9 percent, respectively, over the next five years. In a report published in May, Technavio estimated that the global dietary…

TuesdayJun 05, 2018 10:25 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Engagement of Stadnyk & Partners

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement with Stadnyk & Partners whereby PreveCeutical will engage Stadnyk & Partners to provide market awareness and strategic advisory services to the company. Per the terms of the agreement, Stadnyk & Partners will provide market awareness services to the company throughout the initial 12-month term of the agreement in exchange for two million stock options, each of which will be exercisable to acquire one common share in the capital of PreveCeutical for $0.08 per share for a period of 24 months.…

FridayJun 01, 2018 3:08 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Targets Massive Alternative Medicines Market

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is devoted to developing preventative medical therapies based on the recognized health benefits of natural substances. An article discussing the company reads: “Grandview Research found that the market for alternative medicines was valued at $40.3 billion at the time of its study three years ago. The report found that 60 percent of the world’s population uses some type of traditional or non-conventional medicine, and a separate report by The National Center for Disease Control found that 20 percent of the United States’ population uses alternative therapies, as noted in a Crystal…

TuesdayMay 29, 2018 1:23 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Adding Value to Nature-Identical Therapies Portfolio

Stock split, CSE listing show evidence of company’s shareholder commitment PreveCeutical balancing need for unique profit-building intellectual property with mission to offer affordable products to patients Manufacturer agreement, licensed shipments advance CBD therapy research Alternative medicines market valued at more than $40 billion PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) dedication to developing preventative medical therapies based on the identified health benefits of natural substances in controllable formulations that are both affordable to consumers and potentially profitable to investors is on display in the company’s recent shareholder-approved forward stock split and the opening of trade on the Canadian…

WednesdayMay 23, 2018 1:18 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Posts Update on Forward Stock Split

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), a health sciences company aiming to become a preventive health sciences leader, today announced that, in accordance with the shareholder-approved forward stock split of its issued and outstanding common shares on the basis of five new shares for each existing share, the company's shares have begun trading today on the Canadian Securities Exchange on an "ex-distribution" basis. Per the update, the record date for the stock split has been set at May 24, 2018. To view the full press release, visit http://ibn.fm/l9TQE About PreveCeutical Medical Inc. PreveCeutical is a health sciences…

ThursdayMay 17, 2018 11:32 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Shareholders Approve Proposed Forward Stock Split

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that during its annual general and special meeting of shareholders on May 14, 2018, the proposed forward stock split of PreveCeutical's issued and outstanding common shares on the basis of five new common shares for each one existing common share was approved by the company’s shareholders. Subject to approval by the Canadian Securities Exchange, the record date for the stock split will be May 24, 2018. On or about May 30, 2018, the company's transfer agent will issue the additional number of common shares to…

MondayMay 14, 2018 10:06 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Arrival of Dried Cannabis Materials for Research Program

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the arrival of its second shipment of dried cannabis materials at the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland. Per the update, the shipment came from PreveCeutical’s partner, a Canadian licensed producer. Moving forward, the cannabis materials will be used for the company’s soluble gel (“Sol-gel”) drug delivery research program. The program, which is being led by PreveCeutical Chief Research Officer Dr. Harendra Parekh and conducted by the University of Queensland, involves testing an array of cannabis strains for the development…

Site Search

Company Search

Tag: PreveCeutical Medical Inc. PRVCF